Elekta AB
1EKTA
Company Profile
Business description
Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company has an installed base of more than 7,300 linear accelerators, Gamma Knife and Unity platforms, as well as brachytherapy installations. The company's sales are evenly distributed across geographies, with North and South America accounting for 30%; Europe, the Middle East, and Africa accounting for 36%; and the Asia-Pacific contributing the remainder.
Contact
Hagaplan 4
Box 7593
Stockholm11368
SWET: +46 858725400
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 April 2026
Employees
4,485
Stocks News & Analysis
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
stocks
New production imminent for undervalued ASX gas play
LNG project receives first commissioning gas.
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,324.60 | 40.80 | 0.44% |
| CAC 40 | 8,189.49 | 15.29 | 0.19% |
| DAX 40 | 24,208.65 | 377.66 | 1.58% |
| Dow JONES (US) | 46,396.40 | 205.79 | 0.45% |
| FTSE 100 | 9,400.59 | 46.02 | 0.49% |
| HKSE | 25,858.83 | 611.73 | 2.42% |
| NASDAQ | 22,851.45 | 171.47 | 0.76% |
| Nikkei 225 | 49,185.50 | 1,603.35 | 3.37% |
| NZX 50 Index | 13,344.96 | 55.75 | 0.42% |
| S&P 500 | 6,703.42 | 39.41 | 0.59% |
| S&P/ASX 200 | 9,031.90 | 43.70 | 0.49% |
| SSE Composite Index | 3,863.89 | 24.14 | 0.63% |